APA

Tomova A., Bartsch R., Brodowicz T., Tzekova V., Timcheva C., Wiltschke C., Gerges D. A., Pawlega J., Spanik S., Inbar M. & Zielinski C. C. (20100222). Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). : Breast cancer research and treatment.

Chicago

Tomova Antoaneta, Bartsch Rupert, Brodowicz Thomas, Tzekova Valentina, Timcheva Constanta, Wiltschke Christoph, Gerges Dany Abi, Pawlega Jan, Spanik Stanislav, Inbar Moshe and Zielinski Christoph C. 20100222. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). : Breast cancer research and treatment.

Harvard

Tomova A., Bartsch R., Brodowicz T., Tzekova V., Timcheva C., Wiltschke C., Gerges D. A., Pawlega J., Spanik S., Inbar M. and Zielinski C. C. (20100222). Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). : Breast cancer research and treatment.

MLA

Tomova Antoaneta, Bartsch Rupert, Brodowicz Thomas, Tzekova Valentina, Timcheva Constanta, Wiltschke Christoph, Gerges Dany Abi, Pawlega Jan, Spanik Stanislav, Inbar Moshe and Zielinski Christoph C. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). : Breast cancer research and treatment. 20100222.